BioNTech’s Cancer Pivot Faces Dual Headwinds: Berlin’s Vaccine Demands and Founder Exit
Berlin’s pandemic preparedness contracts are complicating BioNTech’s planned closure of its German COVID-19 vaccine production sites. The federal health ministry confirmed that 7.6 million doses of Comirnaty LP.8.1 still sit...